Skip to content
  • Japanese Website
  • Services
    • Integrated Drug Discovery
    • IND-Enabling Projects
    • Target Identification / Validation
    • Hit Identification / Characterization
    • Lead Generation / Optimization
    • Candidate Selection
    • IND Enabling

    Therapeutics Areas

    • Oncology
    • Immunology
    • Neuroscience
    • Cardiovascular / Metabolic Disease

    Technology Platforms

    • High Throughput Screening

    Therapeutic Modalities

    • Oligonucleotide
    • Peptide
    • Integrated Drug Discovery
      • IND-Enabling Projects
      • Target Identification / Validation
      • Hit Identification / Characterization
      • Lead Generation / Optimization
      • Candidate Selection
      • IND Enabling
    • Therapeutic Areas
      • Oncology
      • Immunology
      • Neuroscience
    • Technology Platforms
      • High Throughput Screening
    • Therapeutic Modalities
      • Oligonucleotide
      • Peptide
  • Events
    • Seminars
    • Conferences
  • Resources
    • Videos
    • Presentations
    • Publications
    • Posters
    • Brochures
  • News
  • About Us
  • Contact
Cardiac QT Risk Assessment Using a Human iPS-cardiomyocytes
Michael Jaramillo2024-06-05T01:30:41+00:0012.05.2023|
  • Integrated Drug Discovery
  • IND-Enabling Projects
  • Target Identification / Validation
  • Hit Identification / Characterization
  • Lead Generation / Optimization
  • Candidate Selection
  • IND Enabling

Therapeutic Areas

  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular / Metabolic Disease

Technology Platforms

  • High Throughput Screening

Therapeutic Modalities

  • Oligonucleotide
  • Peptide

Resources

  • Videos
  • Presentations
  • Publications
  • Posters
  • Brochures

Events

  • Seminars
  • Conferences

About Us

News

Contact
© Copyright Axcelead | Privacy Policy | Cookie Policy
FacebookXInstagramPinterest
Page load link
Go to Top